RegeneRx 'closing in' on eye deal but running on empty
This article was originally published in Scrip
Executive Summary
RegeneRx Biopharmaceuticals says it intends to close a deal by the end of January for its Phase II-stage ophthalmic drug candidate, RGN-259, a sterile, preservative-free topical eye drop formulation of Thymosin beta-4 (TB-4). In the meantime, it is undertaking "additional cost-cutting steps to preserve cash during this period".